FOSTER CITY, Calif. (AP) - Gilead Science Inc.'s earnings tumbled 17 percent in first quarter as sales of its blockbuster hepatitis C franchise slowed faster than expected, missing Wall Street estimates.
The maker of Harvoni, the first once-daily, single-pill regimen for hepatitis C, said sales of the best-selling drug fell 15 percent to $3 billion in the quarter, with the steepest drop-off in the U.
Gilead 1Q profit tumbles on slower hepatitis C drug sales
Aucun commentaire:
Enregistrer un commentaire